Phase I, Open-Label, Safety, Tolerability, and Immunogenicity Study of VGX- 3100 and INO-9012 Delivered by Electroporation (EP) in Women with Cervical Cancer after Chemoradiation
A study for women with cervical cancer using study drugs VGX-3100 and INO-9012
Sponsor: Inovio
Enrolling: Female Patients Only
IRB Number: AAAO4206
U.S. Govt. ID: NCT02172911
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@columbia.edu
Additional Study Information: The purpose of this research study to find out a new way of treating patients with cervical cancer byactivating their immune system to help their body fight the cancer. VGX-3100 and INO-9012 are aninvestigational drug. This means that the drug has not been approved by the Food and DrugAdministration (FDA) for medical use in patients, but has only been approved for use in research.
This study is closed
Investigator
Ana Tergas, MD
Do You Qualify?
Have you been previously been treated for cervical cancer? Yes No
Do you have a confirmed diagnosis of HPV? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE